Tokushima Red Cross Hospital, Tokushima, Japan.
Tokushima Red Cross Hospital, Tokushima, Japan.
Cardiovasc Revasc Med. 2024 Oct;67:19-28. doi: 10.1016/j.carrev.2024.04.006. Epub 2024 Apr 4.
The outcomes after mitral valve transcatheter edge-to-edge repair (M-TEER) for the patients with severe mitral regurgitation (MR) in hemodynamically unstable conditions, such as cardiogenic shock, still remain unclear. We aimed to integrate previous publications regarding M-TEER indicated for life-threatening conditions and indirectly particularly compared the short-term outcomes thereof, with that of other treatments.
We systematically searched the PubMed, Cochrane, and MEDLINE databases for studies from inception to June 2023, regarding M-TEER in patients with hemodynamic instability and severe MR. The primary outcomes analyzed included the in-hospital and 30-day mortality rates, and peri-procedural complications.
Of the initial 820 publications, we conducted a meta-analysis of a total of 25 studies. The relative risk of moderate-to-severe or severe MR was 0.13 (95 % confidence interval [CI]: 0.10-0.18, I = 45.2 %). The pooled in-hospital and 30-day mortality rates were 11.8 % (95 % CI: 8.7-15.9, I = 96.4 %) and 14.1 % (95 % CI: 10.9-18.3, I = 35.5 %), respectively. The 30-day mortality rate was statistically significantly correlated with the residual moderate-to-severe or severe MR, as per the meta-regression analysis (coefficient β = 3.48 [95 % CI: 0.99-5.97], p = 0.006). Regarding peri-procedural complications, the pooled rates of a stroke or transient ischemic attack, life-threatening or major bleeding, acute kidney injury, and peri-procedural mitral valve surgery were 2.3 % (95 % CI: 1.9-2.6), 7.6 % (95 % CI: 6.8-8.5), 32.9 % (95 % CI: 31.6-34.3), and 1.0 % (95 % CI: 0.8-1.3), respectively.
This meta-analysis demonstrates that the relatively higher rates of procedural complications were observed, nevertheless, M-TEER can potentially provide favorable short-term outcomes even in hemodynamically unstable patients.
CRD42023468946.
对于血流动力学不稳定(如心源性休克)的重度二尖瓣反流(MR)患者,经导管二尖瓣瓣环成形术(M-TEER)的转归仍不清楚。我们旨在整合有关危及生命情况下 M-TEER 的既往出版物,并间接比较其短期转归与其他治疗方法的转归。
我们系统地检索了PubMed、Cochrane 和 MEDLINE 数据库,以获取截至 2023 年 6 月有关血流动力学不稳定和重度 MR 患者 M-TEER 的研究。分析的主要结局包括住院和 30 天死亡率以及围手术期并发症。
在最初的 820 篇文献中,我们对总共 25 项研究进行了荟萃分析。中重度或重度 MR 的相对风险为 0.13(95%置信区间:0.10-0.18,I=45.2%)。住院和 30 天死亡率分别为 11.8%(95%置信区间:8.7-15.9,I=96.4%)和 14.1%(95%置信区间:10.9-18.3,I=35.5%)。根据荟萃回归分析,30 天死亡率与中重度或重度 MR 呈显著相关性(系数β=3.48[95%置信区间:0.99-5.97],p=0.006)。关于围手术期并发症,卒中或短暂性脑缺血发作、有生命危险或大出血、急性肾损伤和围手术期二尖瓣手术的发生率分别为 2.3%(95%置信区间:1.9-2.6)、7.6%(95%置信区间:6.8-8.5)、32.9%(95%置信区间:31.6-34.3)和 1.0%(95%置信区间:0.8-1.3)。
本荟萃分析表明,虽然观察到更高的手术并发症发生率,但 M-TEER 即使在血流动力学不稳定的患者中也可能提供有利的短期转归。
PROSPERO 注册号:CRD42023468946。